

Source

Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is a mouse monoclonal antibody produced from hybridoma.

Application

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).

Clone

Y45

Species

Mouse

Isotype

Mouse IgG1/kappa

Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

Immunogen

Recombinant FMC63 scFv derived from HEK293 cells.

Conjugate

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm Emission Wavelength: 535 nm

Isotype Control

The Isotype control is sold separately and you can search for Cat. No. <u>DNP-FM1A1</u> for product information.

Recommended Dilution

1:50

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

Bioactivity-FACS



2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) FITC-Labeled Monoclonal Anti-



FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45)





FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-FY45) and isotype control respectively. FITC signal was used to evaluate the binding activity (QC tested).

Background

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

Clinical and Translational Updates

